All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Pfizer Inc., of New York, completed the submission of a new drug application to the FDA for palbociclib, requesting approval of the compound in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor-positive human epidermal growth factor receptor 2-negative advanced breast cancer who have not received previous systemic treatment for their advanced disease.